These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 7903212)

  • 41. Hemodynamic and pharmacokinetic study of tertatolol in patients with alcoholic cirrhosis and portal hypertension.
    Calès P; Caillau H; Crambes O; Vinel JP; Desmorat H; Rocher I; Jung L; Urien S; Brouard R; Pascal JP
    J Hepatol; 1993 Aug; 19(1):43-50. PubMed ID: 7905493
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Redistribution of cardiac output to the kidneys by tertatolol does not involve prostaglandins.
    Naeije R; Degaute JP
    Am J Hypertens; 1989 Nov; 2(11 Pt 2):241S-244S. PubMed ID: 2573371
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study.
    Giles TD; Weber MA; Basile J; Gradman AH; Bharucha DB; Chen W; Pattathil M;
    Lancet; 2014 May; 383(9932):1889-98. PubMed ID: 24881993
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effect of low dose carvedilol on circadian variation of blood pressure in patients with essential hypertension.
    Ogihara T; Ikeda M; Goto Y; Yoshinaga K; Kumahara Y; Iimura O; Ishii M; Murakami E; Takeda T; Kokubu T
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S108-12. PubMed ID: 2454355
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of the dose--response relationship of aliskiren, a direct renin inhibitor, in an 8-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled study in adult patients with stage 1 or 2 essential hypertension.
    Puig JG; Schunkert H; Taylor AA; Boye S; Jin J; Keefe DL
    Clin Ther; 2009 Dec; 31(12):2839-50. PubMed ID: 20110023
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Renal hemodynamic effects of tertatolol in essential hypertension.
    Paillard F; Lantz B; Leviel F; Ardaillou R
    Am J Nephrol; 1986; 6 Suppl 2():40-4. PubMed ID: 2879472
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of antihypertensive efficacy of carvedilol and nebivolol in mild-to-moderate primary hypertension: a randomized trial.
    Erdoğan O; Ertem B; Altun A
    Anadolu Kardiyol Derg; 2011 Jun; 11(4):310-3. PubMed ID: 21543293
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Once-daily eprosartan mesylate in the treatment of elderly patients with isolated systolic hypertension: data from a 13-week double-blind, placebo-controlled, parallel, multicenter study.
    Punzi HA; Punzi CF
    J Hum Hypertens; 2004 Sep; 18(9):655-61. PubMed ID: 15042114
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment of mild-to-moderate hypertension with calcium channel blockers: a multicentre comparison of once-daily nifedipine GITS with once-daily amlodipine.
    Kes S; Caglar N; Canberk A; Deger N; Demirtas M; Dortlemez H; Kiliccioglu B; Kozan O; Ovunc K; Turkoglu C
    Curr Med Res Opin; 2003; 19(3):226-37. PubMed ID: 12803737
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
    Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR
    J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tertatolol: a beta-blocker with unique effects on human glomerular cell function.
    Shultz P; Raij L
    Cardiology; 1993; 83 Suppl 1():51-6. PubMed ID: 7903216
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Antihypertensive action of various talinolol dosages after four week's treatment in comparison with placebo].
    Weigmann I; Terhaag B; Wierich W; Herrmann WM
    Arzneimittelforschung; 1998 Mar; 48(3):240-4. PubMed ID: 9553680
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A comparative study of metoprolol and trichlormethiazide in hypertension.
    Stokkeland OM; Sangvik K; Ditlefsen EM
    Curr Ther Res Clin Exp; 1975 Dec; 18(6):755-68. PubMed ID: 2449
    [No Abstract]   [Full Text] [Related]  

  • 54. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Rakugi H; Ogihara T; Miyata Y; Sasai K; Totsuka N
    Clin Ther; 2012 Apr; 34(4):838-48. PubMed ID: 22440192
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Recent advances in beta blockade. Therapeutic implications in hypertension. Proceedings of the First International Symposium on Tertatolol, 15th June, 1985, Milano, Italy.
    Am J Nephrol; 1986; 6 Suppl 2():1-116. PubMed ID: 2879463
    [No Abstract]   [Full Text] [Related]  

  • 56. Preserved renal perfusion during beta blockade by tertatolol with and without cyclooxygenase inhibition in normal humans.
    Reuse C; Leeman M; Degaute JP; Abramowicz M; Prost JF; Naeije R
    J Clin Pharmacol; 1988 Apr; 28(4):312-6. PubMed ID: 3134468
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Clinical effect of arotinolol hydrochloride and its influence on renal function in elderly patients with essential hypertension].
    Miyauchi E; Matsumoto M; Kimura Y; Hattori H; Tsukio Y; Tsuchiya H; Takasaki M; Munehira J; Yamada K; Iwai K; Kawanishi K; Hoshino T; Murai H
    Nihon Ronen Igakkai Zasshi; 1999 Aug; 36(8):542-6. PubMed ID: 10554561
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reduction of beta-adrenergic receptors can explain the lack of rebound effect after tertatolol withdrawal.
    De Blasi A; Pittana PL; Fratelli M; Garattini S
    Am J Hypertens; 1989 Nov; 2(11 Pt 2):257S-260S. PubMed ID: 2573373
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tertatolol does not affect biochemical markers of atherosclerosis in normo- and hyperlipidemic hypertensive patients.
    Richard JL; Martin C; Jacotot B
    Am J Nephrol; 1986; 6 Suppl 2():100-5. PubMed ID: 2879464
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prolonged beta blockade due to tertatolol: a comparative study with propranolol and atenolol.
    Desche P; Cournot A; Guery O; Prost JF; Duchier J
    Fundam Clin Pharmacol; 1987; 1(4):253-6. PubMed ID: 3501763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.